| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-044 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 第三届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届董事会第八次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯表决的方式召开。会议通知及材料于 2025 年 8 月 18 日以电话、微信等通讯方式送达。会议由公司董事长系祖斌主持，会 议应到董事 7 人，实际参会董事 7 人，独立董事何德良以通讯表决方式出席会议。 公司高级管理人员列席了本次会议。 本次会议的召开符合《中华人民共和国公司法》（以下简称《公司法》）《湖 北共同药业股份有限公司章程》（以下简称《公司章程》）《湖北共同药业股份有 限公司董事会议事规则》的规定，会议决议合法有效。 二、董事会会议审议情况 经全体董事认真审议并表决，会议审议通过了以下议案： （一）审议通过《关于 ...

数据显示，共同药业5日均线为23.35元，10日均线为23.63元，5日均线较10日均线距离为-1.16%，呈现 均线死叉形态。该股最新价较10日均线乖离率为-2.56%。 资金流向方面，共同药业当日主力资金净流出106.29万元，占流通市值的0.06%。近五个交易日累计净 流出4117.22万元，占流通市值的2.33%。 风险提示：股市有风险，投资需谨慎。 截至2025年8月26日收盘，共同药业股价报23.02元，较前一交易日下跌1.29%。盘中最高触及23.37元， 最低下探至22.98元，成交量为38546手，成交金额为0.89亿元。 共同药业属于化学制药行业，公司主营业务为甾体药物原料的研发、生产及销售。公司产品主要包括性 激素、孕激素等甾体药物原料，下游应用领域涵盖医药制剂、保健品等行业。 ...

Group 1 - The core viewpoint of the news is that Hubei Gongtong Pharmaceutical Co., Ltd. has shown a decline in net profit despite an increase in total revenue, indicating potential challenges in profitability [1] - As of August 12, 2025, the company's stock price closed at 23.5 yuan, down 2.89%, with a trading volume of 81,400 hands and a transaction amount of 193 million yuan [1] - The latest quarterly report shows total revenue of 139 million yuan, a year-on-year increase of 13.90%, while net profit attributable to shareholders decreased by 69.50% to 1.08 million yuan [1] Group 2 - The company has a current ratio of 1.055, a quick ratio of 0.531, and a debt-to-asset ratio of 65.26%, indicating its liquidity and financial leverage [1] - Hubei Gongtong Pharmaceutical has made investments in 7 companies and participated in 15 bidding projects, showcasing its active engagement in the market [2] - The company holds 5 trademark registrations and 59 patents, along with 293 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

（文章来源：证券日报） 证券日报网讯 8月6日晚间，共同药业发布公告称，公司第三届董事会第七次会议审议通过了《关于全 资子公司购买资产暨关联交易的议案》。 ...

（文章来源：证券日报） 证券日报网讯 8月6日晚间，共同药业发布公告称，公司第三届监事会第六次会议审议通过了《关于全 资子公司购买资产暨关联交易的议案》。 ...

Group 1: National Grid and Electricity Demand - National Grid's electricity load reached a historical high of 1.233 billion kilowatts from August 4 to 6, an increase of 53 million kilowatts compared to last year's peak of 1.180 billion kilowatts [1] - The load is expected to remain above 1.2 billion kilowatts on August 7, with a potential decrease later in the week due to rain and cooler temperatures [1] Group 2: Gaming Laptop Market - The Chinese consumer gaming laptop market saw a year-on-year growth rate of 24.3% in Q2 2025, significantly outpacing the overall consumer PC market [1] - This growth is driven by the demand for high-performance devices from university students and core gaming enthusiasts, as well as the rapid evolution of gaming content [1] Group 3: Real Estate and Office Leasing - Adidas will establish its new Greater China headquarters in a 32,400 square meter office building in Shanghai's West Bund, expected to be completed in Q1 2026 [2] - This leasing transaction is one of the largest in Shanghai's Grade A office market in 2023 [2] Group 4: Bankruptcy and Financial Performance - Claire's, a fashion jewelry manufacturer, filed for bankruptcy protection for the second time since 2018, with estimated assets and liabilities between $1 billion and $10 billion [2] - Evergrande Real Estate Group has recently been executed for over 1.67 billion yuan, with a total of over 55.9 billion yuan in outstanding execution amounts [2] Group 5: Financial Results - Jerry Holdings reported a net profit of 1.241 billion yuan for the first half of 2025, a year-on-year increase of 14.04% [6] - Tiantan Biological's net profit for the same period was 633 million yuan, reflecting a year-on-year decrease of 12.88% [7] - Shunbo Alloy achieved a net profit of 177 million yuan, marking a significant year-on-year increase of 110.56% [8] Group 6: Market Performance - The Shanghai Composite Index rose by 0.45% with a trading volume of 1.73 trillion yuan, indicating a broad market rally with over 3,300 stocks rising [9] - PEEK material concept stocks and military stocks saw significant gains, while pharmaceutical stocks experienced a downturn [10]

Group 1 - Jerry Holdings reported a net profit of 1.241 billion yuan for the first half of 2025, an increase of 14.04% year-on-year, with total revenue reaching 6.901 billion yuan, up 39.21% year-on-year [1] - Tian Tan Biological announced a net profit of 633 million yuan for the first half of 2025, a decrease of 12.88% year-on-year, with total revenue of 3.110 billion yuan, an increase of 9.47% year-on-year [2] - Shunbo Alloy achieved a net profit of 177 million yuan for the first half of 2025, a significant increase of 110.56% year-on-year, with total revenue of 7.126 billion yuan, up 11.75% year-on-year [7] Group 2 - Dashi Intelligent signed a contract for the Jingpai Building smart project with a total contract value of 34.06 million yuan, accounting for 1.07% of the company's audited revenue for 2024 [3] - Maglev Technology plans to invest 700 million yuan to establish a research and production base for maglev compressors, aiming to optimize product structure and enhance production capacity [4] - Koweil received government subsidies totaling 5.502 million yuan, which are expected to positively impact the company's profits for 2025 [5] Group 3 - Pengding Holdings reported a consolidated revenue of 3.002 billion yuan for July 2025, an increase of 12.28% compared to the same period last year [9] - Liuyou Group repurchased 544,500 shares at a price range of 18.29 to 18.36 yuan per share, totaling approximately 9.9828 million yuan [10] - Jin Xin Nong reported a sales revenue of 96.731 million yuan from pig sales in July 2025, with a total of 79,400 pigs sold [12] Group 4 - Jiangsu Huachen plans to use up to 70 million yuan of idle raised funds for cash management, investing in safe and liquid financial products [13] - Gongtong Pharmaceutical's subsidiary intends to purchase assets from an affiliate for 16.57 million yuan to build a wastewater treatment facility [15] - Tian Shi Li appointed Wang Yimin as the vice general manager, effective immediately [16] Group 5 - Zhejiang Yongqiang established a subsidiary in Indonesia with a registered capital of 230 billion Indonesian rupiah, focusing on overseas capacity investment and international trade [18] - Wangli Security received three invention patents, enhancing its product portfolio in security locks [20] - Shennong Group reported a sales revenue of 327 million yuan from pig sales in July 2025, with an average selling price of 14.73 yuan per kilogram [21] Group 6 - Dize Pharmaceutical's product DZD8586 received fast track designation from the FDA for treating relapsed refractory chronic lymphocytic leukemia [23] - Daqin Railway reported a cargo transportation volume of 31.79 million tons in July 2025, a year-on-year increase of 5.40% [24] - Xin Hongye's subsidiary won a bid for a nuclear-grade cable procurement project worth 81.58 million yuan [26] Group 7 - Hainan Hengbo established a wholly-owned subsidiary with a registered capital of 50 million yuan, focusing on technology services and new material technology research [26] - Changhong Huayi reported a net profit of 257 million yuan for the first half of 2025, an increase of 13.42% year-on-year, with total revenue of 6.628 billion yuan [27] - Haiguang Information achieved a net profit of 1.201 billion yuan for the first half of 2025, an increase of 40.78% year-on-year, with total revenue of 5.464 billion yuan [28] Group 8 - Dongmu Co. reported a net profit of 261 million yuan for the first half of 2025, an increase of 37.61% year-on-year, with total revenue of 2.930 billion yuan [29] - Hanma Technology announced the resignation of its executive vice president due to personal reasons [30] - Guangge Technology's shareholders plan to reduce their holdings by up to 4.04% of the company's shares [31] Group 9 - *ST Energy's subsidiary won a bid for an independent energy storage project with a total bid price of 320 million yuan for design and 301 million yuan for construction [32] - Chipeng Micro plans to reduce its holdings by up to 2% of the company's shares due to personal financial needs [33] - Ancar Detection announced a change in its controlling shareholder to Silicon Technology, with stock resuming trading [35] Group 10 - Dahao Technology's vice president is temporarily unable to perform duties due to health reasons [36] - Sanjiang Shopping's cooperation agreement with Hema will not be renewed after its expiration in March 2026 [37] - Huisheng Biological reported a net profit of 117 million yuan for the first half of 2025, a year-on-year increase of 325.88% [38] Group 11 - Dongshan Precision plans to increase capital in its subsidiary by 3.5 billion USD to support high-end PCB projects [39] - Yunnan Copper's subsidiary's bankruptcy liquidation application has been accepted by the court due to resource depletion [40] - Shanghai Bank's board member and chairman's qualifications have been approved by regulatory authorities [41] Group 12 - Junwei Electronics plans to acquire 100% of Flat Electronics Co., Ltd. for 2.6 billion yen to enter the film resistor market [42] - Daodaoquan's controlling shareholder plans to increase its stake in the company by 50 million to 100 million yuan [43] - Yinglian Co.'s subsidiary signed a strategic cooperation agreement with a well-known cylindrical battery company [45] Group 13 - Debang Technology's state integrated circuit fund plans to reduce its holdings by up to 3% of the company's shares [47] - Tianyi New Materials plans to sell part of its subsidiary's assets for 51.4 million yuan to improve cash flow [49] - Rongtai Co. intends to acquire 51% of Zhongshan Aoduo for 288 million yuan [51]

证券代码：300966 证券简称：共同药业 公告编号：2025-041 转债代码：123171 转债简称：共同转债 湖北共同药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届董事会第七次会议于 议应到董事 7 人，实际参会董事 7 人，独立董事龙子午、祁飞、何德良以通讯表决 方式出席会议。公司高级管理人员列席了本次会议。 本次会议的召开符合《中华人民共和国公司法》《湖北共同药业股份有限公司 特此公告。 湖北共同药业股份有限公司 章程》《湖北共同药业股份有限公司董事会议事规则》的规定，会议决议合法有效。 二、董事会会议审议情况 经全体董事认真审议并表决，会议审议通过了以下议案： 审议通过《关于全资子公司购买资产暨关联交易的议案》 经审议，董事会认为：全资子公司购买资产暨关联交易事项符合子公司业务发 展的需要，遵循了平等自愿、互惠互利、公平公允的原则。 本议案在提交公司董事会审议前已经公司独立董事专门会议审议通过。 具体内容详见公司同日在巨潮资讯网（www.cninfo.co ...